liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Targeting of solid tumors and blood malignancies by antibody-based therapies - EGFR-pathway as an example
Department of Chemotherapy, M. Sklodowska-Curie Oncology Center, 31-115, Krakow, Poland .
Bonifratrow Monastyr Hospital, 31-061, Krakow, Poland.
Department of Medical Genetics, Tehran University of Medical Sciences, 14155-6447, Tehran, Iran; Manitoba Institute of Cell Biology, CancerCare Manitoba, University of Manitoba, Winnipeg, Manitoba, Canada; Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Canada .
Department of General Biology, Silesian Medical School, 41-808, Zabrze, Poland.
Show others and affiliations
2006 (English)In: Central European Journal of Biology, ISSN 1895-104X, Vol. 1, no 2, 167-182 p.Article in journal (Refereed) Published
Abstract [en]

A well-coordinated interaction between extracellular signals and intracellular response forms the basis of life within multicellular organisms, with growth factors playing a crucial role in these interactions. Discoveries in recent years have shown that components of the Epidermal Growth Factor (EGF) signaling system have frequently been used by cancer cells to autonomously provide survival and proliferation signals. The main focus of this review is the ErbB epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases including ErbB1/EGFR, ErbB2/HER2/neu, ErbB3/HER3, and ErbB4/HER4 as therapeutic targets. Since the ErbB receptor family regulates cell proliferation through the Ras-mitogen-activated protein kinase (RAS/MAPK) pathway, and cell survival and transformation through the phosphatidylinositol 3-kinase (PI3K/AKT) pathway, pharmacological targeting of these pathways is also discussed. We will also address the clinical studies that have been conducted to evaluate antibody-based therapies mostly on solid tumors and hematologic malignancies. (c) Versita Warsaw and Springer-Verlag Berlin Heidelberg. All rights reserved.

Place, publisher, year, edition, pages
Versita , 2006. Vol. 1, no 2, 167-182 p.
Keyword [en]
Apoptosis, breast-cancer, cell-survival, chronic lymphocytic-leukemia, growth-factor receptor, metastatic colorectal-cancer, monoclonal-antibody, ovarex, plus irinotecan, primary prostate-cancer, theragyn, triab, tyrosine kinase inhibitor, zamyl, zevalin
National Category
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy) Cancer and Oncology Biochemistry and Molecular Biology
URN: urn:nbn:se:liu:diva-86984DOI: 10.2478/s11535-006-0014-6ISI: 000246983000001OAI: diva2:584102
Available from: 2013-01-08 Created: 2013-01-08 Last updated: 2013-09-03

Open Access in DiVA

fulltext(393 kB)5333 downloads
File information
File name FULLTEXT01.pdfFile size 393 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Los, Marek Jan
In the same journal
Central European Journal of Biology
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)Cancer and OncologyBiochemistry and Molecular Biology

Search outside of DiVA

GoogleGoogle Scholar
Total: 5333 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 60 hits
ReferencesLink to record
Permanent link

Direct link